Cohance Lifesciences Intrinsic Value
Cohance Lifesciences (COHANCE) median intrinsic value is ₹823.47 from 8 valuation models (range ₹131–₹1095), vs current price ₹438.00 — +88.0% upside (Trading Below Calculated Value), margin of safety 46.8%. For current market price and key ratios, visit Cohance Lifesciences share price screener.
COHANCE Valuation Methods Summary — DCF, Graham Number & P/E
Cohance Lifesciences intrinsic value across 8 models vs current price ₹438.00 — upside/downside and value range per method. Check COHANCE market value to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹131.40 | ₹105.12 - ₹157.68 | -70.0% | EPS: ₹2.04, Sector P/E: 22x |
| Book Value Method | asset | ₹1095.00 | ₹985.50 - ₹1204.50 | +150.0% | Book Value/Share: ₹1061.58, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹876.00 | ₹788.40 - ₹963.60 | +100.0% | Revenue/Share: ₹649.47, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹842.11 | ₹757.90 - ₹926.32 | +92.3% | EBITDA: ₹320.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹823.47 | ₹658.78 - ₹988.16 | +88.0% | CF Growth: 2.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹131.40 | ₹118.26 - ₹144.54 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹131.40 | ₹118.26 - ₹144.54 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹220.74 | ₹198.67 - ₹242.81 | -49.6% | EPS: ₹2.04, BVPS: ₹1061.58 |
COHANCE Intrinsic Value vs Market Price — All Valuation Models
Cohance Lifesciences fair value range ₹131–₹1095 vs current market price ₹438.00 across 8 valuation models. See COHANCE P/B ratio to compare market price against book value per share.
COHANCE Intrinsic Value Analysis — Undervalued or Overvalued?
Cohance Lifesciences median intrinsic value ₹823.47, current price ₹438.00 — Trading Below Calculated Value by 88.0%, margin of safety 46.8%.
What is the intrinsic value of COHANCE?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Cohance Lifesciences (COHANCE) is ₹823.47 (median value). With the current market price of ₹438.00, this represents a +88.0% variance from our estimated fair value.
The valuation range spans from ₹131.40 to ₹1095.00, indicating ₹131.40 - ₹1095.00.
Is COHANCE undervalued or overvalued?
Based on our multi-method analysis, Cohance Lifesciences (COHANCE) appears to be trading below calculated value by approximately 88.0%.
COHANCE Financial Health — Key Ratios vs Industry Benchmarks
Cohance Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.71 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 0.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.43x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
COHANCE Cash Flow Quality — Operating & Free Cash Flow
Cohance Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹368 Cr | ₹243 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹673 Cr | ₹479 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹359 Cr | ₹178 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹457 Cr | ₹360 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹330 Cr | ₹262 Cr | Positive Free Cash Flow | 8/10 |